文献速递流行病学与生物统计真实世界研究与卫生经济

1975至2019年美国乳腺癌死亡率分析

Analysis of Breast Cancer Mortality in the US-1975 to 2019.
PubMed 文献 · JAMA · 2024-01-01

使用4个CISNET模型模拟1975至2019年美国30至79岁女性乳腺癌死亡率,评估筛查、I至III期治疗和转移性治疗与死亡率降低的相对关联。2019年三种干预合计与58%死亡率降低相关,其中I至III期治疗占47%、转移性治疗占29%、筛查占25%。

要点

  • 2019年筛查、I至III期治疗和转移性治疗合计与乳腺癌死亡率降低58%相关(模型范围55%-61%)。
  • 死亡率降低中,I至III期治疗占47%(模型范围35%-60%),转移性治疗占29%(模型范围19%-33%),筛查占25%(模型范围21%-33%)。
  • 转移复发后生存改善最大出现在2000至2019年,中位生存从1.9年(模型范围1.0-2.7年)延长至3.2年(模型范围2.0-4.9年)。

核心结论

  • 据4个模拟模型,2019年筛查和治疗与1975年干预相比,与美国乳腺癌死亡率降低58%相关。
  • 模拟提示I至III期治疗与约47%的死亡率降低相关,转移性治疗与29%相关,筛查与25%相关。

研究设计与样本

  • 使用4个癌症干预与监测建模网络(CISNET)模型,基于筛查和治疗传播及效果的汇总观察性和临床试验数据,模拟美国乳腺癌死亡率。
  • 模拟1975至2019年美国30至79岁女性乳腺癌死亡,包括总体及按雌激素受体和ERBB2(原HER2)状态。

主要发现

  • 美国年龄调整乳腺癌死亡率1975年为48/100000女性,2019年为27/100000女性。
  • 2019年筛查、I至III期治疗和转移性治疗合计与58%死亡率降低相关(模型范围55%-61%)。
  • 死亡率降低中,转移性治疗占29%(模型范围19%-33%),I至III期治疗占47%(模型范围35%-60%),钼靶筛查占25%(模型范围21%-33%)。
  • 转移复发后生存最大改善出现在2000至2019年,中位生存从1.9年(模型范围1.0-2.7年)延长至3.2年(模型范围2.0-4.9年)。
  • 雌激素受体(ER)阳性/ERBB2阳性乳腺癌中位生存改善2.5年(模型范围2.0-3.4年),ER阴性/ERBB2阴性乳腺癌中位生存改善0.5年(模型范围0.3-0.8年)。

关键数值与推荐

  • 2019年筛查、I至III期治疗和转移性治疗合计与58%死亡率降低相关(模型范围55%-61%)。
  • 死亡率降低中,I至III期治疗占47%(模型范围35%-60%),转移性治疗占29%(模型范围19%-33%),筛查占25%(模型范围21%-33%)。
  • 转移复发后中位生存2000至2019年从1.9年(模型范围1.0-2.7年)延长至3.2年(模型范围2.0-4.9年)。
  • ER阳性/ERBB2阳性乳腺癌中位生存改善2.5年(模型范围2.0-3.4年),ER阴性/ERBB2阴性乳腺癌中位生存改善0.5年(模型范围0.3-0.8年)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Breast cancer mortality in the US declined between 1975 and 2019. The association of changes in metastatic breast cancer treatment with improved breast cancer mortality is unclear. OBJECTIVE: To simulate the relative associations of breast cancer screening, treatment of stage I to III breast cancer, and treatment of metastatic breast cancer with improved breast cancer mortality. DESIGN, SETTING, AND PARTICIPANTS: Using aggregated observational and clinical trial data on the dissemination and effects of screening and treatment, 4 Cancer Intervention and Surveillance Modeling Network (CISNET) models simulated US breast cancer mortality rates. Death due to breast cancer, overall and by estrogen receptor and ERBB2 (formerly HER2) status, among women aged 30 to 79 years in the US from 1975 to 2019 was simulated. EXPOSURES: Screening mammography, treatment of stage I to III breast cancer, and treatment of metastatic breast cancer. MAIN OUTCOMES AND MEASURES: Model-estimated age-adjusted breast cancer mortality rate associated with screening, stage I to III treatment, and metastatic treatment relative to the absence of these exposures was assessed, as was model-estimated median survival after breast cancer metastatic recurrence. RESULTS: The breast cancer mortality rate in the US (age adjusted) was 48/100 000 women in 1975 and 27/100 000 women in 2019. In 2019, the combination of screening, stage I to III treatment, and metastatic treatment was associated with a 58% reduction (model range, 55%-61%) in breast cancer mortality. Of this reduction, 29% (model range, 19%-33%) was associated with treatment of metastatic breast cancer, 47% (model range, 35%-60%) with treatment of stage I to III breast cancer, and 25% (model range, 21%-33%) with mammography screening. Based on simulations, the greatest change in survival after metastatic recurrence occurred between 2000 and 2019, from 1.9 years (model range, 1.0-2.7 years) to 3.2 years (model range, 2.0-4.9 years). Median survival for estrogen receptor (ER)-positive/ERBB2-positive breast cancer improved by 2.5 years (model range, 2.0-3.4 years), whereas median survival for ER-/ERBB2- breast cancer improved by 0.5 years (model range, 0.3-0.8 years). CONCLUSIONS AND RELEVANCE: According to 4 simulation models, breast cancer screening and treatment in 2019 were associated with a 58% reduction in US breast cancer mortality compared with interventions in 1975. Simulations suggested that treatment for stage I to III breast cancer was associated with approximately 47% of the mortality reduction, whereas treatment for metastatic breast cancer was associated with 29% of the reduction and screening with 25% of the reduction.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Caswell-Jin JL, Sun LP, Munoz D, et al. Analysis of Breast Cancer Mortality in the US-1975 to 2019. JAMA. 2024. PMID: 38227031. doi:10.1001/jama.2023.25881

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。